Traders selecting between iShares U.S. Healthcare ETF (NYSEMKT:IYH) and VanEck Biotech ETF (NASDAQ:BBH) might weigh the broader, lower-volatility healthcare publicity of IYH towards the concentrated, high-growth biotechnology focus of BBH.
Traders selecting between the biotechnology subsector and the broader healthcare trade usually weigh excessive development potential towards portfolio stability. Whereas BBH focuses on 25 biotech companies, IYH contains 100 corporations, like pharmaceutical giants and gear makers. This comparability examines how these completely different methods impression prices, dangers, and yields.
Snapshot (value & measurement)
Beta measures value volatility relative to the S&P 500; beta is calculated from five-year month-to-month returns. The 1-yr return represents complete return over the trailing 12 months. Dividend yield is the trailing-12-month distribution yield.
BBH is barely extra inexpensive with a 0.35% expense ratio in comparison with 0.38% for IYH. Nevertheless, IYH supplies a extra important payout, providing a 1.20% dividend yield in comparison with 0.50% for the biotech-focused fund.
Efficiency & threat comparability
What’s inside
The iShares U.S. Healthcare ETF (IYH) supplies broad publicity throughout the healthcare sector, which accounts for 100.00% of its portfolio. Its largest positions embrace Eli Lilly (NYSE:LLY) at 15.96%, Johnson & Johnson (NYSE:JNJ) at 10.42%, and Abbvie Inc (NYSE:ABBV) at 7.30% amongst its 100 complete holdings. The fund was launched in 2000. iShares U.S. Healthcare ETF has paid $0.80 per share over the trailing 12 months, which, at its current ~$68.56 share value, yields 1.20%.
The VanEck Biotech ETF (BBH) focuses on 25 corporations concerned in genetic analysis and diagnostics, with 100.00% of its portfolio allotted to the healthcare sector. Prime holdings embrace Amgen Inc (NASDAQ:AMGN) at 14.84%, Gilead Sciences Inc (NASDAQ:GILD) at 13.21%, and Vertex Prescription drugs Inc (NASDAQ:VRTX) at 9.16%. The fund was launched in 2011. VanEck Biotech ETF has paid $0.96 per share over the trailing 12 months, which, at its current ~$209.28 share value, yields 0.50%.
For extra steerage on ETF investing, take a look at the total information at this hyperlink.
Which seems to be like the higher purchase
The iShares U.S. Healthcare ETF (IYH) and the VanEck Biotech ETF (BBH) are each healthcare-focused exchange-traded funds (ETFs). Here is how they examine to 1 one other.
First, let’s take a more in-depth take a look at IYH. This fund is centered on the U.S. healthcare sector. Certainly, the fund’s excessive publicity to main healthcare giants is a double-edged sword. Totally 45% of its complete publicity is concentrated in simply 5 shares: Eli Lilly (16%), Johnson & Johnson (10%), AbbVie (7%), UnitedHealth Group (6%), and Merck (5%). In consequence, this fund lacks true diversification, regardless of holding round 100 shares. A lot of its efficiency will merely come from the rise of the healthcare giants. Turning to efficiency, the fund has delivered a complete return of 153% during the last decade, equating to a compound annual development price (CAGR) of 9.7%. Against this, the S&P 500 has delivered a complete return of 317% over this similar interval, with a CAGR of 15.3%. This complete return contains the impression of the fund’s modest 1.2% dividend yield.
Then there’s BBH. This fund differs from IYH in its sector focus. BBH is a biotech ETF. The fund holds solely 25 positions, with important publicity to Amgen, Gilead, Vertex, Regeneron, and Revolution Medicines. Biotech shares can usually be unstable, given their reliance on clinical-stage therapies and the outcomes of the governmental approval course of. Over the long run, BBH has underperformed IYH. Since 2016, the fund has delivered a complete return of 98%, equating to a CAGR of seven.1%. This complete return contains the fund’s dividend yield, presently 0.5%.
Each funds supply buyers publicity to the healthcare sector, albeit in very completely different kinds. IYH is a fund that may usually observe the efficiency of healthcare giants, whereas BBH gives higher upside (and volatility) given its holdings within the biotech sector. As for charges, each funds have expense ratios which are common at greatest. BBH is barely extra inexpensive at 0.35%, versus 0.38% for IYH. To sum up, IYH could also be the popular alternative for buyers in search of healthcare-only publicity, although alternate options supply higher diversification at a decrease value.
Must you purchase inventory in iShares Belief – iShares U.s. Healthcare ETF proper now?
Before you purchase inventory in iShares Belief – iShares U.s. Healthcare ETF, take into account this:
The Motley Idiot Inventory Advisor analyst crew simply recognized what they imagine are the 10 greatest shares for buyers to purchase now… and iShares Belief – iShares U.s. Healthcare ETF wasn’t considered one of them. The ten shares that made the reduce may produce monster returns within the coming years.
Take into account when Netflix made this record on December 17, 2004… when you invested $1,000 on the time of our advice, you’d have $395,679!* Or when Nvidia made this record on April 15, 2005… when you invested $1,000 on the time of our advice, you’d have $1,294,805!*
Now, it is value noting Inventory Advisor’s complete common return is 929% — a market-crushing outperformance in comparison with 211% for the S&P 500. Do not miss the most recent prime 10 record, obtainable with Inventory Advisor, and be a part of an investing neighborhood constructed by particular person buyers for particular person buyers.
See the ten shares »
*Inventory Advisor returns as of July 11, 2026.
Jake Lerch has positions in Merck. The Motley Idiot has positions in and recommends AbbVie, Amgen, Eli Lilly, Gilead Sciences, Merck, Regeneron Prescription drugs, and Vertex Prescription drugs. The Motley Idiot recommends Johnson & Johnson and UnitedHealth Group. The Motley Idiot has a disclosure coverage.
Which is the Higher Selection for Healthcare Traders? IYH or BBH? was initially revealed by The Motley Idiot
